Editas Medicine (EDIT) Reports Q3 Loss of $0.66
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Editas Medicine Announces Third Quarter 2019 Results and Update
November 12, 2019 7:02 AM ESTAmended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine
Appointed Judith R. Abrams, M.D., as Chief Medical Officer
EDIT-101 (AGN-151587) for LCA10 first patient dosing expected by early 2020
EDIT-301 for hemoglobinopathies in vivo pre-clinical data to be presented at ASH
CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for... More
